|
|
|
|
|
Legal status
Patent in force
| (51) | INT.CL. | C07K 14/47 | (2006.01) |
| C12N 15/113 | (2015.01) |
| (11) | Number of the document | 3083677 |
| (13) | Kind of document | T |
| (96) | European patent application number | 14821860.5 |
| Date of filing the European patent application | 2014-12-18 | |
| (97) | Date of publication of the European application | 2016-10-26 |
| (45) | Date of publication and mention of the grant of the patent | 2019-08-28 |
| (46) | Date of publication of the claims translation | 2019-12-10 |
| (86) | Number | PCT/IB2014/067076 |
| Date | 2014-12-18 |
| (87) | Number | WO 2015/092737 |
| Date | 2015-06-25 |
| (30) | Number | Date | Country code |
| 201361919340 P | 2013-12-20 | US |
| (72) |
JOSTOCK, Thomas, CH
LAUX, Holger, CH
RITTER, Anett, CH
|
| (73) |
Novartis AG,
Lichtstrasse 35, 4056 Basel,
CH
|
| (74) |
Jurga PETNIŪNAITĖ,
AAA Law, A. Goštauto g. 40B, Verslo centras "Dvyniai", LT-03163 Vilnius,
LT
|
| (54) | Naujos eukariotinės ląstelės ir dominančio polipeptido rekombinantinės raiškos būdai |
| NOVEL EUKARYOTIC CELLS AND METHODS FOR RECOMBINANTLY EXPRESSING A PRODUCT OF INTEREST |
| Payment date | Validity (years) | Amount | |
| 2025-11-18 | 12 | 289.00 EUR |
| 2026-12-18 |